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Abstract 
Background: As the prevalence of the malaria has been decreasing in many endemic countries including Myanmar, 
malaria elimination in Greater Mekong Region was targeted not later than 2030. The relevance of molecular and sero‑
logical tools to identify residual transmission remains to be established in this setting.
Methods: One‑year cohort study was conducted and sera samples were collected in every 3 months with active and 
passive case detection for clinical malaria episodes by RDT, microscopy and molecular method. The sera were used to 
detect the malaria antibody against PfMSP1‑19, PvAMA1, PvDBPII and PvMSP1‑19 by protein microarray.
Results: Among the recruited 1182 participants, there was no RDT positive case for malaria infection although two 
vivax infections were detected by microscopy in initial collection. Molecular methods detected the asymptomatic 
cases of 28/1182 (2.37%) in first, 5/894 (0.42%) in second, 12/944 (1.02%) in third, 6/889 (0.51%) in fourth collec‑
tion, respectively. Seropositivity rates against the PfMSP1‑19, PvMSP1‑19, PvAMA1 and PvDBPII were 73/270 (27.0%), 
85/270 (31.5%), 65/270 (24.1%) and 160/270 (59.3%), respectively. PfMSP1‑19 and PvMSP1‑19 showed high and stable 
antigenicity in acute and subacute samples but declining in 1‑year history samples. No cross reactivity of PfMSP1‑19 
and PvMSP1‑19 between the two species and higher seropositivity among the asymptomatic carriers were observed. 
Mapping data indicated serological surveillance can detect the geographical pattern of malaria infection under low 
transmission setting.
Conclusions: These findings support that PfMSP1‑19 and PvMSP1‑19 are suggested for serosurveillance of the 
malaria especially in low transmission setting for further necessary actions have to be carried out to eliminate the 
malaria.
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Background
In the era of (pre) elimination of malaria, surveillance 
is vital to estimate the local transmission of malaria 
[1]. Under the (pre) elimination phase, only sporadic 
cases are common and very few cases of fevers are due 
to malaria. Imported cases may represent the major-
ity of the disease burden [2]. Currently, parasitological 
based cases detection with active and passive approach is 
widely used to detect and treat the clinical cases in the 
community [3]. Although the World Health Organization 
(WHO) recommends the parasitological diagnosis using 
rapid diagnostic tests (RDTs) or peripheral blood smear 
examination by microscopy, the detection limits of the 
above methods are not satisfactory to detect the low level 
parasitaemia [4]. Although molecular based detection 
methods are developed, these methods cannot be used 
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widely in most of the field conditions because of the tech-
nical constraints and cost. Moreover, as the parasite den-
sities fluctuate over time, leading to temporal variation in 
the detectability of infections and cross sectional analy-
sis of the parasitological based detection method cannot 
estimate the local transmission of malaria correctly. To 
overcome it, one of the promising approaches is serologi-
cal surveillance.
Unlike many other infectious diseases, malaria antibod-
ies against the parasite antigens are widely diverted and 
some may last for long duration [5, 6]. As the antibody 
status may not reflect the acute malaria infection, it is not 
a suitable tool for diagnosis [7]. However, malaria anti-
body shows the local transmission profile indicating the 
indigenous malaria cases in the community [8]. Moreo-
ver, malaria antibody level was higher in older age assum-
ing the cumulative exposure of the antigens. Significant 
lower level of malaria antibody was observed in high atti-
tude reflecting the local transmission. In hyper endemic 
areas, local transmission of malaria can be assessed by 
malariometric survey and antigen assays as malaria cases 
are detected throughout the year. Under low endemic set-
ting, malaria antibody is suggested for estimation of hot-
spot by estimation on the geographical pattern of malaria 
transmission [9]. However, malaria antibody shows the 
complexity in nature, resulting from species, stage and 
strain specific antigen diversity [10–12]. Moreover, age 
specific antibody response was reported that may reflect 
the cumulative exposure or behaviour-related differences 
in exposure [13].
Although malaria serological analysis was reported, 
there are no validated serological marker(s), no stand-
ardized high accuracy detection platform and no inter-
pretation approach [14]. Many studies were focusing on 
antibodies against the exo-erythrocytic and erythrocytic 
stages of the parasite. In this study, seroepidemiology and 
serokinetics of the PfMSP1-19, PvMSP1-19, PvDBPII and 
PvAMA1 were assessed to evaluate the usefulness as the 
serological markers for local transmission of malaria.
Methods
Study design and study population
One-year longitudinal follow-up sample collections were 
done in Shwegyin Township (22° 20′ 0″ N, 95° 56′ 0″ E), 
one of the Tier I areas of Myanmar Artemisinin Resist-
ance Containment (MARC) areas in 2015. Because of the 
nearby gold mines, many migrant workers were working 
in these areas and malaria was notified as one of the lead-
ing diseases in Shwegyin and evidence on drug resistant-
malaria was documented [15]. It has been selected as one 
of the township for elimination programme initiated in 
Myanmar.
Sample size determination
Required sample size has been calculated by PASS sam-
ple size software (version 13, NCSS, USA). As this study 
was carried out as a longitudinal observational cohort, 
group sequential Log-rank test has been applied assum-
ing 90% power to detect the hazard rate 0.76 when the 
proportions sero-conversion in each group were 0.3 and 
0.4 at a significant level (alpha) of 0.05 using a two-sided 
Log-rank test for the four sequential tests in each active 
sample collection. The required minimal sample size is 
884. Loss to follow-up had to be assumed 20% in each 
time and the sample size had to be 1060 in minimum.
Sample collection procedures
The participants in this study were recruited by rand-
omized cluster sampling in Shwegyin Township. Inclu-
sion criteria included minimum age of 5  year, both 
sex and local residents in the study area for more than 
3 years. As the study aimed to conduct a follow-up lon-
gitudinal study up to 1 year, the migrant or mobile popu-
lations were excluded. The person who currently showed 
the severe sign and symptoms of malaria was also not 
included in this study.
At each visit, 1  mL of the whole blood was collected 
from the fore arm of the participants under aseptic con-
dition. The sera was extracted from the blood and kept 
at − 80 °C until analysis. The remaining whole blood was 
used for malaria parasite detection as described below.
Sampling procedure
Randomized cluster sampling method was used in this 
study. According to the distribution of the local health 
centers, two out of the four centers were randomly 
selected. Then, all villages were listed, from which seven 
villages were randomly selected. Among them, sampling 
interval was calculated to get the required samples in the 
villages i.e., at least 151 per village. Household visit or pub-
lic meeting places were used to collect the samples based 
on the convenience of the participants. Active case detec-
tion was done in every 3 months until 1 year and passive 
case detection was carried out by local health personnel.
Malaria naïve samples
For negative control, healthy sera were collected from the 
people of the Republic of Korea who had no exposure to 
malaria. A total of 96 healthy malaria-naïve individuals 
were collected and they were 6–13 years old with mean 
age of 10 years.
Detection on asymptomatic infection
Rapid diagnostic test (RDT) (PfHRPII and Pv specific 
pLDH based assay, SDFK80, Standard Diagnostics, 
Republic of Korea), microscopy and molecular method 
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using nested PCR amplifying the small subunit ribosomal 
RNA, were used for detection of asymptomatic malaria 
infection in all samples collected in every 3  months as 
described details previously [16, 17].
All malaria infections were treated according to the 
National Malaria Treatment Guideline of Myanmar. 
Briefly, artemisinin-based combinational therapy (ACT) 
with primaquine stat dose for falciparum infection, chlo-
roquine followed by 14  days course of primaquine in 
vivax infection and chloroquine for malaria infection.
Serokinetic screening by protein microarray
Among the collected samples, 685 (57.95%) attended all 
four visits. Among them, 270 samples were selected after 
excluding of the possible confounding factors, i.e., two 
cohorts in which composed of less than 15 years-old and 
more than 15 years-old samples in which equal distribu-
tion of male and female, and history of malaria (Fig. 1).
The procedures for protein array were described previ-
ously [18]. Briefly, amine coated slides were prepared. For 
microarray screening, 1  µL of optimized concentrations 
(25  ng/µL for PvMSP1-19, 12.5  ng/µL for PfMSP1-19, 
100 ng/µL for PvDBPII and PvAMA1) was spotted into 
each wells of the arrays and incubated for 2  h at 37  °C. 
Then the slides were washed with PBS-Tween (0.1%) for 
10 min followed by distilled water washing for 5 min. The 
array slides were then blocked with 5% BSA in PBS-T 
(PBS with 0.1% Tween) for 1  h at 37  °C. After washing 
again, the slides were probed with plasma collected from 
the patients and healthy control individual (1:25 dilution). 
Alexa Fluor 546-conjugated goat anti-human IgG (10 ng/
µL, Invitrogen, Carlsbad, CA, USA) in PBS-T was used 
as the detection antibody and the signals were detected 
in a fluorescence scanner (InnoScan 300, Innopsys, Car-
bonne, France). The Mapix software was used for data 
acquisition and analysis. All samples were duplicated in 
the same slides. Mean values of two mean fluorescence 
intensity (MFI) were calculated.
Cross reaction analysis
To assess the cross reactivity of the recombinant antigens 
between falciparum and vivax, protein microarray using 
pooled clinical falciparum, pooled clinical vivax and neg-
ative control pooled samples, was used in the same array 
slide with duplicated spots followed by the same proce-
dures described above [19].
Data analysis
Data was checked and analysed by using Microsoft excel 
and IBM SPSS Statistics (version 23, International Busi-
ness Machines Corp., Armonk, NY, USA). Pearson’s Chi 
squared test was used to determine association with a p 
value of < 0.05 accepted as significant. Logistic regression 
was calculated using the selected independent variables 
to estimate the outcome variables. Mann–Whitney test 
was used to for nonparametric analysis on non-normal 
distribution. For microarray data, mean fluorescence 
intensity (MFI) data were normalized and transformed by 
vsn method with asinh (hyperbolic arc sine) using R-pro-
gram [20]. The cut-off value was defined as two standard 
variation (SD)s above the transformed MFI of malaria 
naïve individual. Mapping for surveillance of the malaria 
cases by molecular method, PCR comparing with sero-
logical response against PvDBPII, PvAMA1, PvMSP1-19 
and PfMSP1-19 was carried out. The map was generated 
as described previously using ARC GIS and SaTScan 
software [21]. Circular window was used to scan system-
atically adjusting with the percent positive among the 
participants in each villages. As the village level output 
is not provided by this software, final map was generated 
by the Photoshop CS3 software. In the map, the relative 
size of the circular windows for seropositive in each of 
One year follow-up samples
Less than 15 year
(n=150)
Female 
(n=75)
More than 15 year
(n=120)
Male 
(n=75)
Past history (+) (n=26)
Past history (-) (n=39)
Not sure (n=10)
Past history (+) (n=18)
Past history (-) (n=39)
Not sure (n=18)
Female 
(n=60)
Male 
(n=60)
Past history (+) (n=40)
Past history (-) (n=20)
Not sure (n=10)
Past history (+) (n=40)
Past history (-) (n=20)
Not sure (n=18)
Fig. 1 Selection of the sera for serological assessment among the participants
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the antigens in the study areas focusing on the geographi-
cal distribution of the malaria parasitaemia (by molecu-
lar) contracted with malaria serology positive (by protein 
microarray) were generated. The data include all four 
active sample collections in accordance with the sample 
size calculation by Sequential Rank Test.
Ethical approval and consent to participate
The study was conducted only after receiving the ethi-
cal approval from Institutional Ethical Committee of the 
Department of Medical Research, Myanmar (Approval 
number 49/Ethics-2014). It was also registered with 
ClinicalTrial.gov (Identifier: NCT02708199). Written 
informed consents were taken in all of the participants. 
Participation in this study was entirely voluntary. All 
detected malaria cases were treated according to the 
national anti-malarial treatment guideline in Myanmar. 
The personal information collected in this study was kept 
confidential.
Results
Demographic characteristics of the study population
In this study, a total of 1182 local residents were recruited 
to study. Passive case detection was carried out by 
local health authorities and local malaria volunteers to 
detect the clinical malaria episodes. Active case detec-
tion and field blood sample collections were conducted 
one in every 3 months until 1 year. A total of 685 (58.0%) 
attended all four visits (Table 1).
Detection of asymptomatic infection
All collected samples were checked for asymptomatic 
parasitaemia by RDT, microscopy and nested PCR. 
Although there was no RDT positive case, two cases in 
visit 1 were detected as P. vivax infections (parasite den-
sities of 580 and 1200 parasites per µL, respectively). 
Among the participants, 39 showed asymptomatic infec-
tion by PCR and 12 were detected vivax infection in more 
than one visit (Table 1).
Initial screening of selected candidate antigens for malaria 
antibody kinetic analysis
The purified recombinant target antigens were used 
to screen the four visits collected plasma samples of 
270 participants by protein microarray. A total of 1080 
plasma samples (1:25 dilution) and 98 healthy sera were 
included to analyze. Among the candidate serological 
markers, PvDBPII showed the highest seropositivity: 
160/270 (59.3%) in at least one visit of sample collection, 
followed by PvMSP1-19 antigen 85/270 (31.5%), PfMSP1-
19 antigen 73/270 (27.0%) and PvAMA1 antigen 65/270 
(24.1%), respectively.
Similarly, overall seropositivity in four times visits (V1-
V4) data showed the highest rate in PvDBPII (31.7%), 
followed by PvMSP1-19 (17.7%), PfMSP1-19 (14.5%) 
and PvAMA1 (9.9%), respectively. PvDBPII showed the 
highest seropositivity and stable level among the study 
population in all four visits. Similarly, PfMSP1-19 showed 
the stable antigenicity among the population. However, 
PvMSP1-19 seropositivity showed the highest antigenic-
ity in V4. Interestingly, PvAMA1 seropositivity was low-
est in V4 (Fig. 2).
When the age group (< 15 and > 15 year) was consid-
ered as a factor that may contribute to the seropositivity 
of the candidate antigens, only PfMSP1-19 and PvDBPII 
showed higher seropositivity in old age group (p = 0.000 
and p  =  0.004). However, there was no association 
between the seropositivity of the antigens and sex of the 
participants (Table 2).
Similarly, there was no association between the pre-
vious history of malaria and antibody seropositive rate 
except in PfMSP1-19 that showed the significant associa-
tion (p = 0.0025). All antigens showed high seropositivity 
among the asymptomatic infection. PfMSP1-19 showed 
3/4 (75.0%) seropositivity among asymptomatic falcipa-
rum infection while PvMSP1-19 showed 39/51 (76.5%) 
seropositivity among the asymptomatic vivax infection. 
Similarly, PvDBPII and PvAMA1 showed 37/51 (72.5%) 
Table 1 Basic demographic characteristics of  the study 
population
a Asymptomatic cases were detected by nested PCR
Total recruited participants 1182
Age in year (median, IQR) 30 (18–45)
Sex (M:F) 4:5
History of malaria (n, %) 549 (46.4)
History of malaria within 1 year (n, %) 71 (6.0)
History of malaria within 1–3 years (n, %) 215 (18.2)
History of malaria more than 3 years (n, %) 263 (22.2)
Visit 1 (V1) collection (n = 1182, 100.0%)
 All asymptomatic  casesa 30 (2.5%)
 P. vivax 24
 P. falciparum 4
 P. malariae 2
Visit 2 (V2) collection (n = 894, 75.6%)
 Asymptomatic cases 6 (0.7%)
 P. vivax 6 (0.7%)
Visit 3 (V3) collection (n = 944, 79.9%)
 Asymptomatic cases 13 (2.5%)
 P. vivax 13 (2.5%)
Visit 4 (V4) collection (n = 889, 75.2%)
 Asymptomatic cases 8 (0.9%)
 P. vivax 8 (0.9%)
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and 38/51 (74.5%), respectively among the asymptomatic 
vivax infection (Table 2).
Among 270 samples, only 28/270 (10.4%) showed 
co-seropositivity against PvMSP1-19 and PfMSP1-19 
antigens. On the other hand, PvMSP1-19 seropositiv-
ity alone accounted for 57/270 (21.1%) and PfMSP1-
19 seropositivity alone for 45/270 (16.7%). When 
PfMSP1-19 and PvDBPII seropositivity rates were com-
pared, 49/270 (18.2%) showed co-seropositivity. While 
PfMSP1-19 seropositivity alone accounted for 24/270 
(8.9%), PvDBPII seropositivity alone was 111/270 
(41.1%). Similarly, seropositivity rates of PfMSP1-19 
and PvAMA1 were compared and 13/270 (4.8%) were 
seropositive against both antigens. Similar seropositiv-
ity rate against the PfMSP1-19 alone (60/270, 22.2%) 
and that against PvAMA1 alone (52/270, 19.3%) was 
observed.
Among the three vivax antigens, seropositivity rates of 
PvMSP1-19 and PvDBPII were compared as these two 
candidates showed the highest seropositivity rate. Only 
50/270 (18.5%) were seropositive against both antigens. 
While 110/270 (40.7%) were seropositive against PvDB-
PII only, 35/270 (13.0%) of the samples showed seroposi-
tivity against PvMSP1-19 (p = 0.0034).
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Fig. 2 Seropositivity of the four different antigens among four visit (V1–V4)
Table 2 Seropositivity against four different antigens in study population
Category PfMSP1-19 PvMSP1-9 PvAMA1 PvDBPII
n (%) p n (%) p n (%) p n (%) p
Age (year)
 < 15 18 (30.0) 0.000 45 (12.0) 0.599 43 (28.7) 0.062 77 (51.3) 0.004
 > 15 55 (33.3) 40 (45.8) 22 (18.3) 83 (69.2)
Sex
 Male 40 (29.6) 0.411 36 (26.7) 0.116 34 (25.2) 0.776 73 (54.1) 0.107
 Female 33 (24.4) 49 (36.3) 31 (23.0) 87 (64.4)
History of malaria within 3 years
 Yes 40 (32.2) 0.025 46 (37.1) 0.098 27 (21.8) 0.710 75 (60.5) 0.171
 No 31 (26.3) 29 (24.6) 31 (26.3) 73 (61.9)
 Not sure 2 (7.1) 10 (35.7) 7 (25.0) 12 (42.9)
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Serological response among the four vivax antigens 
among vivax subclinical cases indicated that all antibody 
level were stable up to 1  year after infection except in 
PvMSP1-19 which showed significant reduction of mean 
fluorescence intensity in 9  months after treatment of 
infection (Fig. 3).
Geographical patterns in seropositivity and parasitaemia
When mapping was done to detect the malaria geographi-
cal patterns of malaria in seropositivity compared with 
parasitaemia in the samples collected in active case detec-
tion by PCR, the PvMSP1-19 showed the similar pattern of 
the local transmitted areas with that by molecular method. 
PvAMA1 and PvDBPII showed the high seropositivity in 
the villages at which very few vivax asymptomatic cases 
were identified by PCR, suggesting the long-lasting anti-
body response against these antigens (Fig. 4).
Discussion
Malaria serology is a cornerstone in estimation on local 
transmission of malaria. Although there are many stud-
ies on malaria serology [22–24], there is no standardized 
method for recombinant antigens production, no stand-
ardized approach for detection of antibody status and no 
validated antigen for all transmission setting.
In this study, the recombinant antigens; PfMSP1-19, 
PvMSP1-19, PvAMA1 and PvDBPII were screened in 
1080 samples collected from 270 participants in every 
3 months for 1 year. Among them, the highest seroposi-
tivity was observed in PvDBPII, followed by PvMSP1-19, 
PfMSP1-19 and PvAMA1.
PvDBPII is the most interesting vaccine candidate 
and widely studied for vaccine [25]. However, antibody 
responses showed the relationship with the heterogene-
ity of the parasite population [26]. The humoral immune 
antibody response against PvDBPII is high and stable in 
the population regardless of the history of past infection 
in the present study. Serological markers should not be 
the vaccine candidate to exclude the humoral immune 
response induced by vaccine [27]. Moreover, a higher 
seropositivity rate of PvDBPII was observed in older age 
group indicating the long-lasting nature of the antibody 
[5]. Due to the long-lasting antibody status and potential 
vaccine candidate, PvDBPII is not suitable for serological 
marker to estimate the local transmission of malaria.
The humoral immune response against PvMSP1-19 
also showed the stable kinetic among all four sample 
collections in this study. The presence of the PfMSP1-
19 antibody can prevent against the parasitaemia and 
malaria related febrile illness [28]. Not only the AMA1 
but also the MSP1-19 antibody were found to have 
protective activity against symptomatic malaria [29]. 
However, vaccine-induced antibody was not protective 
against the vaccine-dissimilar strains due to the strain 
specific antibody response [30]. Moreover, high and sta-
ble seropositivity was also noted in all four visit collec-
tions leading to consider a potential vaccine candidate. 
High polymorphism in PvAMA1 gene influences the 
antigen specific response that limit the usefulness of the 
PvAMA1 as vaccine or serological marker [31].
One study conducted in Uganda [32] found that 
MSP1-19 seroprevalence and parasite prevalence were 
Fig. 3 Serokinetic of the vivax antigens among the asymptomatic vivax infected cases
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decreased in high attitude hilly region, indicating the 
usefulness as a serological tool to estimate local transmis-
sion of malaria. In this study, both falciparum and vivax 
MSP1-19 antibodies were found to be stable. The pres-
ence of the antibody may prevent against the clinical or 
even asymptomatic infection. Moreover, antibody against 
MSP1-19 was observed in no longer than 9 months after 
infection indicating its usefulness as a serological marker 
to track the local transmission of malaria under low 
transmission setting.
Fig. 4 Mapping of the seroprevalence of the four different targets and molecular confirmed subclinical cases. The size of the circle represents the 
relative percent of the positive cases
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Moreover, there was no cross reactivity of MSP1-19 
antibody among the all four common Plasmodium spe-
cies [33]. It was found that very low or no cross reactiv-
ity of MSP1-19 antibody to falciparum and vivax among 
the two natural infections, reflecting the low amino acid 
identity (40.2%) between the two species. Discrimina-
tion between the two species; falciparum and vivax is an 
important issue in the area previously or currently occu-
pied by both species.
Interestingly, there was no malaria case among local 
resident populations by passive case detection while 
molecular method can detect the subclinical infection 
of 2.5, 0.7, 2.5 and 0.9% of the samples collected on visit 
1–4. Most of them were vivax infection as a usual finding 
of the (pre)elimination area where previously occupied 
by both falciparum and vivax malaria. However, a limited 
number of the PCR confirmed asymptomatic cases were 
not allowed to analyze the correlation of the seropositiv-
ity rate between asymptomatic cases and non-infected 
samples.
Moreover, MSP1-19 antibody responses were similar 
geographical distribution to the parasitological based 
detection using PCR. Both falciparum and vivax MSP1-
19 antibodies were found to be stable up to 9  months 
after infection, then decreased significantly indicating the 
promising candidates to be used to assess local transmis-
sion of malaria under low transmission setting.
One limitation of this study is that the strain specific 
antibody responses in the community against the strain 
specific antigen(s) were not determined. This may affect 
the overall seroprevalence of the antigens. Moreover, 
this study was conducted as a longitudinal observational 
study under low transmission setting for only 1  year 
period. To validate the evidence, a multisite cross sec-
tional study including control site should be conducted in 
a different endemic setting.
Conclusions
In summary, estimation on local transmission of malaria is 
a fundamental information for priority assessment, strat-
egy making, planning, implementation and evaluation of 
the interventions in all malarious areas. Routine methods 
based on phenotypic and genotypic characteristics are 
not sensitive enough to estimate the local transmission of 
malaria in the community. Serological surveillance using 
the recombinant PfMSP1-19 and PvMSP1-19 may pro-
vide an alternate tool for estimation on local transmission 
of malaria under low transmission settings.
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